WuXi

WuXi Xpress White Paper: RNA therapeutics to become a dominant treatment modality within a decade

New Delhi, July 27, 2019: Industry experts speaking within a newly released WuXi Xpress White Paper on RNA have identified 2019 as potentially…

5 years ago

Syngene announces Q1 FY20 results

Revenue up 4% to Rs. 441 Cr, Profit After Tax increases 9% to 72 Cr; Dr. Mahesh Bhalgat appointed Chief…

5 years ago

WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA. Shanghai, May 03, 2018: STA…

7 years ago